CX3CL1 and Alzheimer disease: Importantly, treatment with AST and AST-LI significantly restored brain levels of CX3CL1 and GFAP compared to AD-like controls (Fig. 8), suggesting a possible mechanism for AST’s anti-inflammatory effect through fractalkine pathway activation [81, 82] and suppression of astrocytic activation [83, 84].